Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
In Reply: In response to Drs Bonicalzi and
Canavero, we acknowledge that our short trial cannot be considered the sole
method of validating the long-term efficacy of intrathecal ziconotide. Our
design, however, provided sufficient time to determine that ziconotide provided
effective pain relief with minimal adverse effects and to offer our participants
continued pain management using the novel agent in a second, open-label, compassionate
trial, during which we continued to collect safety and efficacy data.
Staats PS. Intrathecal Ziconotide for Chronic Pain—Reply. JAMA. 2004;292(14):1681-1682. doi:10.1001/jama.292.14.1682-a